BiomX Inc.

BiomX Inc. (NYSE American: PHGE) is a clinical-stage biopharmaceutical company developing phage-based therapies that selectively target disease-associated bacteria within the human microbiome, with programs spanning infectious and inflammatory diseases. The company became publicly traded in October 2019 through a business combination with Chardan Healthcare Acquisitions Corp., a blank-check vehicle sponsored by Chardan Capital Markets that completed its initial public offering in 2018. On July 28, 2026, BiomX filed an 8-K with the SEC under accession number 0001213900-26-082025, disclosing a material corporate event. Full filing details, SPAC deal history, and real-time data on PHGE are available on SpacDesk — sign up today for complete access.